Next-Generation Ultra-Wideband to Power 1.4 Billion Devices by 2030 as Ecosystem Matures and Applications Diversify

Ultra-Wideband (UWB) is rapidly becoming a foundational wireless connectivity technology, offering unique benefits compared with other short-range wireless solutions such as Wi-Fi, Bluetooth®, IEEE 802.15.4, and Near Field Communication (NFC). The combination of secure ranging, radar, and sensing capabilities, along with its potential to serve as a low-latency, high-throughput communications technology over short distances, is […]

Biofrontera Inc. announces sale of license to Xepi(R) Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

(NASDAQ:BFRI),(NASDAQ:BFRIW), Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability. Proceeds will support the growth of Biofrontera's commercial photodynamic therapy (PDT) platform,

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

(Madrid:ORY.MC),(Boerse Stuttgart – Freiverkehr:ORN),(Madrid:ORY),(Boerse Stuttgart – Freiverkehr:ORN.SG), The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS (Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmit Reinforcing company's clinical,

Vaxart to Host Upcoming Conference Calls

(NASDAQ:VXRT),(OTC US:VXRT),(Other OTC:VXRT), Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast

Pelthos Therapeutics Acquires Xepi(R) (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

(NYSE MKT:PTHS), Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI(TM) Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children Impetigo affects approximately 3 million people in the U.S. every year and

Black Friday Starts Early at Curacao: Three Weeks of Massive Savings You Can’t Miss

LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) — Curacao, one of the largest Hispanic-focused retailers on the West Coast, is jumpstarting the holiday shopping season with three consecutive weeks of Early Black Friday Deals packed with savings across hundreds of must-have products. Beginning today, shoppers can snag Black Friday prices weeks early with massive markdowns

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

(Other OTC:KARX),(OTC US:KARX), CONAKRY, Guinea, Nov. 07, 2025 (GLOBE NEWSWIRE) — Building on the success of its 7,000-hectare mangrove reforestation project in Senegal–which has already generated an estimated 2.8 million tonnes of COâ‚‚ reductions and measurable community benefits–Karbon-X Corp. (OTCQX:KARX) (“Karbon-X” or the “Company”) is expanding its blue carbon leadership into the Konkoure Delta of

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

(NASDAQ:AIRJ), RONAN, Mont., Nov. 07, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading platform technology that unleashes the power of water from air, today announced that it will report its third quarter 2025 results after market close on Thursday, November 13, 2025. Company management will host a

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting(R) 2025

– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups – – In addition to robust liver-centric effects, HU6 resulted in fat-selective weight loss with preservation of skeletal muscle mass; potential to address the metabolic dysfunction underlying MASH – – HU6 was well tolerated in M-ACCEL, with

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call

(NYSE:DY), WEST PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2026 third quarter results on Wednesday, November 19, 2025, at 9:00 a.m. ET. Dycom will issue a press release reporting its results earlier that morning. Interested parties may participate in the

Scroll to Top